Sign in
Taking people in United StatesPhase 2

Gene therapy 4D-710 for adults with cystic fibrosis lung disease

Tests a new gene medicine given once to adults with cystic fibrosis lungs.

Key facts

Who runs it
4D Molecular Therapeutics
Where
Baltimore, Birmingham, Boston, Chapel Hill, Charleston, Chicago, Cleveland, Columbus, Dallas, Denver, Gainesville, Hershey, Kansas City, Miami, Philadelphia, Richmond, San Francisco, Seattle, and Tucson, United StatesSee the 20 sites
Trial code
Registry title
4D-710 in Adult Patients With Cystic Fibrosis
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
29 Mar 2022
Expected to end
Jun 2031
Type of study
Interventional, 3 groups
Treatments tested
  • 4D-710
Record updated
6 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cystic fibrosis and cystic fibrosis lung disease, to test a single dose of the gene therapy 4D-710.

Age
18 years and older
Sex
All sexes can join.
Disease stage
Confirmed cystic fibrosis with lung disease and sweat chloride of 60 mmol/L or more. Lung function (FEV1) must be 50% to 90% of predicted in the main study, and 40% to under 70% (or at least 2 flare-ups in the last year needing intravenous antibiotics) in the sub-study. Resting oxygen saturation must be 92% or more on room air in the main study.
Earlier treatment
Main study: cannot take CFTR modulator therapy, or took it before and stopped because of side effects. Sub-study: on a stable dose of CFTR modulator therapy for at least 60 days before screening. No prior gene therapy of any kind (mRNA or antisense therapies are allowed).
Biomarker or test result
Two CFTR gene mutations, or one CFTR mutation together with signs of cystic fibrosis lung disease.

Main reasons for not taking part

  • Any earlier gene therapy (except mRNA or antisense therapy)
  • Active Mycobacterium abscessus infection needing treatment
  • Smoking or vaping in the last 2 months
  • Needing long-term steroid or immune-suppressing medicine, or being unable to take steroids
  • Needing oxygen all the time or at night, or a body mass index (BMI) below 16

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • 18 years and older
  • Confirmed diagnosis of cystic fibrosis (CF) and CF lung disease including:; Sweat chloride ≥ 60 mmol/L; Mutation Status; Bi-allelic mutations in the CFTR gene, or; Single mutation in the CFTR gene and clinical manifestations of CF lung disease; Ineligible for CFTR modulator therapy, or previously received modulator therapy but discontinued due to adverse effects
  • Forced expiratory volume in 1 second (FEV1) ≥ 50% and ≤ 90% of predicted (per Global Lung Function Initiative) at Screening
  • Resting oxygen saturation ≥ 92% on room air at Screening
  • 18 years and older
  • Confirmed diagnosis of cystic fibrosis (CF) and CF lung disease including:; Sweat chloride ≥ 60 mmol/L; Mutation Status; Bi-allelic mutations in the CFTR gene, or; Single mutation in the CFTR gene and clinical manifestations of CF lung disease
  • Currently on a stable dose of CFTR modulator therapy for a minimum of 60 days prior to Screening and agree to maintain current regimen through the 24-month Observation Period
  • FEV1 ≥ 40% and < 70% predicted (per Global Lung Function Initiative) at Screening, AND/OR experienced at least 2 pulmonary exacerbations in the last year requiring intravenous antibiotics

Who cannot take part

  • Any prior gene therapy for any indication (Exception: mRNA-based or antisense oligonucleotide therapies are not exclusionary)
  • Smoking (e.g. cigarettes, cigars, cannabis) or use of a vaping product during the 2 months prior to screening; must agree to not smoke or use vaping products during Screening and initial 24-month observation period
  • Contraindication to systemic corticosteroid therapy
  • Active Mycobacterium abscessus infection requiring ongoing treatment at Screening
  • Active allergic bronchopulmonary aspergillosis requiring management with systemic corticosteroids or antifungal therapy
  • Requires chronic use of systemic corticosteroids or immunosuppressants to treat another condition
  • Other conditions that, in the Investigator's opinion, may interfere with management of corticosteroid-related hyperglycemia
  • Known CF liver disease with evidence of multilobular cirrhosis
  • History of thrombosis (excluding catheter-related thrombosis) or conditions associated with increased risk of thrombosis
  • If no known diagnosis of cystic fibrosis related diabetes (CFRD), Type I, or Type II diabetes: Hemoglobin A1C ≥ 6.5% at Screening
  • If known diagnosis of CFRD, Type I or Type II diabetes: Hemoglobin A1C > 7.5% at Screening
  • Recent history of symptomatic hyperglycemia or unstable blood glucose levels as per Investigator's assessment
  • Laboratory abnormalities at screening:; ALT, AST or GGT ≥ 3 × the upper limit of normal (ULN); Total bilirubin ≥ 2 × ULN; Hemoglobin < 10 g/dL
  • Body Mass Index (BMI) < 16
  • Requirement for continuous or night-time oxygen supplementation

Where in United States

  • Johns Hopkins HospitalBaltimore, United StatesContact: Kaia HoutmanTaking people
  • University of Alabama Child Health Research UnitBirmingham, United StatesContact: Justin AndersonTaking people
  • Boston Children's HospitalBoston, United StatesContact: Monica UllesTaking people
  • Massachusetts General HospitalBoston, United StatesContact: Margot HardcastleTaking people
  • University of North Carolina at Chapel HillChapel Hill, United StatesContact: 4DMT Patient AdvocacyNo longer taking part
  • Medical University of South CarolinaCharleston, United StatesContact: Cameron MathisonTaking people
  • Northwestern Memorial HospitalChicago, United StatesContact: Rachel NelsonTaking people
  • Rainbow Babies and Children's Hospital / University Hospitals Cleveland Medical CenterCleveland, United StatesContact: Tia RoneTaking people
  • Nationwide Children's HospitalColumbus, United StatesContact: Terri JohnsonTaking people
  • The University of Texas Southwestern Medical CenterDallas, United StatesContact: Maria McLeodTaking people
  • National Jewish HealthDenver, United StatesContact: Jennifer Taylor-Cousar, MDTaking people
  • University of FloridaGainesville, United StatesContact: Chrystal BaileyTaking people
  • Penn State HealthHershey, United StatesContact: 4DMT Patient AdvocacyNo longer taking part
  • University of Kansas Medical CenterKansas City, United StatesContact: Lawrence ScottTaking people
  • University of Miami HospitalMiami, United StatesContact: Ivan WhitakerTaking people
  • The Hospital of the University of PennsylvaniaPhiladelphia, United StatesContact: Melissa MolterTaking people
  • Virginia Commonwealth University Health SystemRichmond, United StatesContact: Margaret K. LessardTaking people
  • University of California San FranciscoSan Francisco, United StatesContact: Legna BetancourtTaking people
  • University of Washington Medical CenterSeattle, United StatesContact: Roshni PrabhuTaking people
  • The University of ArizonaTucson, United StatesContact: Elizabeth RyanTaking people

About the trial

What the trial wants to find out

This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.

The 3 groups in the trial

  • 4D-710 Phase 1: Dose ExplorationTreatment being tested

    Participants who are ineligible for or intolerant of modulator therapy will receive one of various dose levels of 4D-710 to identify recommended phase 2 dose(s) for further evaluation.

    Treatment: 4D-710

  • 4D-710 Phase 2: Dose ExpansionTreatment being tested

    Participants will receive a single inhalational administration of 4D-710 at the dose level(s) selected for dose expansion.

    Treatment: 4D-710

  • 4D-710 Dose Exploration (Sub-Study)Treatment being tested

    Participants who are on currently available CFTR modulator therapy will receive a dose of 4D-710 at various dose levels.

    Treatment: 4D-710

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-710 in Adults With Cystic Fibrosis
Plain-language title
Gene therapy 4D-710 for adults with cystic fibrosis lung diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
6 July 2026